Elicit: Bleeding Risks and Reversal of Factor Xa Inhibitors
Bleeding risk mechanisms and reversal strategies for factor Xa inhibitors
Abstract
Bleeding with factor Xa inhibitors occurs predominantly as intracranial hemorrhage (64-69%) or gastrointestinal bleeding (23-52%) in elderly patients (mean age 76-78 years) with substantial comorbidities, including kidney insufficiency in 48% and atrial fibrillation as the primary anticoagulation indication in 81%. Andexanet alfa, administered as a bolus followed by 2-hour infusion, reduces anti-factor Xa activity by 92-94% for apixaban and rivaroxaban and achieves excellent or good clinical hemostasis in 67-82% of patients. In the randomized ANNEXA-I trial, andexanet demonstrated superior hemostatic efficacy compared to usual care (primarily 4F-PCC) for intracerebral hemorrhage (67.0% vs 53.1%), but was associated with higher rates of thrombotic events (10.3% vs 5.6%), particularly ischemic stroke (6.5% vs 1.5%). Thrombotic events consistently occurred before anticoagulation resumption, with no events after oral anticoagulation restart, indicating that thrombotic risk results from interruption of anticoagulation rather than rebound effects. Reduction in anti-FXa activity was modestly predictive of hemostatic efficacy specifically in patients with intracranial hemorrhage and correlated with lower mortality in younger patients, suggesting that the benefit of aggressive reversal is context-dependent and modified by patient age and bleeding location.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Results
The review included 10 studies examining bleeding risk mechanisms and reversal strategies for factor Xa inhibitors. Studies varied in design from randomized controlled trials to retrospective cohorts and reviews.
Characteristics of Included Studies
| Study | Full Text Retrieved? | Study Type | Sample Size | FXa Inhibitors | Primary Focus |
|---|---|---|---|---|---|
| Stuart J Connolly et al., 2016 | No | Prospective single-group (ANNEXA-4 prelim) | 67 patients, 47 in efficacy analysis | Rivaroxaban, apixaban | Andexanet reversal efficacy |
| S. Connolly et al., 2019 | No | Prospective single-group (ANNEXA-4 full report) | 352 patients, 249 evaluable | Apixaban, rivaroxaban, enoxaparin | Andexanet reversal efficacy |
| T. Milling et al., 2023 | Yes | Prospective single-group (ANNEXA-4 final) | 479 patients, 342 evaluable | Apixaban (51%), rivaroxaban (37%) | Andexanet reversal efficacy |
| Stuart J. Connolly et al., 2024 | Yes | Randomized controlled trial (ANNEXA-I) | 530 patients (263 andexanet, 267 usual care) | Apixaban, rivaroxaban | Andexanet vs usual care for ICH |
| T. Kłosiewicz et al., 2017 | No | Retrospective 5-center cohort | 56 patients | Factor Xa inhibitors (unspecified) | Real-world reversal approaches |
| T. Milling et al., 2017 | Yes | Retrospective 5-center cohort | 56 patients | Rivaroxaban, apixaban, enoxaparin | Real-world reversal approaches |
| J. Abdulrehman et al., 2019 | No | Critical review | Review of ANNEXA-4 data | Apixaban, rivaroxaban | Andexanet evidence review |
| Elise M. L. Carpenter et al., 2019 | Yes | Clinical review | Review of phase I-III trials | Apixaban, rivaroxaban, edoxaban, enoxaparin | Andexanet pharmacology and efficacy |
| R. Grandhi et al., 2015 | No | Retrospective single-center | 18 patients | Rivaroxaban (16 patients), apixaban (2 patients) | 4F-PCC for ICH reversal |
| Ioannis Milioglou et al., 2022 | No | Retrospective single-center comparison | 45 patients (23 andexanet, 22 4F-PCC) | Apixaban (64% of patients) | Andexanet vs 4F-PCC for ICH |
Bleeding Risk Mechanisms
Patient-specific risk factors for bleeding with FXa inhibitors included advanced age, with mean ages of 76-78 years across studies, and significant comorbidities. In the largest cohort, 48% of patients had kidney insufficiency, 28% had diabetes, 23% had prior stroke, and 20% had heart failure.
Reversal Strategies
Reversal strategies varied across studies, with andexanet alfa and 4-factor prothrombin complex concentrate (4F-PCC) being the primary agents used. Andexanet alfa was administered as a bolus followed by a 2-hour infusion, with dosing based on the specific FXa inhibitor, its dose, and time since last dose. Two andexanet dosing regimens were employed: low-dose (400 mg bolus + 480 mg infusion) and high-dose (800 mg bolus + 960 mg infusion).
Laboratory Reversal Efficacy
Andexanet alfa demonstrated rapid and substantial reductions in anti-factor Xa activity across all FXa inhibitors studied. The magnitude and durability of reduction varied by specific agent.
| FXa Inhibitor | Baseline Anti-FXa Activity | Post-Bolus Anti-FXa Activity | Reduction |
|---|---|---|---|
| Apixaban | 149.7 ng/mL | 11.1 ng/mL | 92-93% |
| Rivaroxaban | 211.8 ng/mL | 14.2 ng/mL | 92-94% |
| Edoxaban | 121.1 ng/mL | 24.4 ng/mL | 71% |
| Enoxaparin | 0.48 IU/mL | 0.11 IU/mL | 75% |
Clinical Hemostatic Efficacy
Hemostatic efficacy ratings were assessed, with 171 excellent, 33 good, and 45 poor outcomes observed. In the randomized ANNEXA-I trial focusing on intracerebral hemorrhage, hemostatic efficacy was achieved in 67.0% of patients receiving andexanet compared to 53.1% receiving usual care.
Safety Outcomes
Thrombotic events represented the primary safety concern, with rates and timing varying across studies. In-hospital mortality rates were significant, with substantial variance among studies, primarily due to cardiovascular causes in the cohort studied.